PURPOSE: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to understand the biologic underpinnings of HGBL-DH/TH with BCL2 rearrangements (HGBL-DH/TH- BCL2) and diffuse large B-cell lymphoma (DLBCL) morphology through examination of gene expression. PATIENTS AND METHODS: We analyzed RNA sequencing data from 157 de novo germinal center B-cell-like (GCB)-DLBCLs, including 25 with HGBL-DH/TH- BCL2, to define a gene expression signature that distinguishes HGBL-DH/TH- BCL2 from other GCB-DLBCLs. To assess the genetic, molecular, and phenotypic features associated with this signature, we analyzed targeted resequencing, whole-exome sequencing, RNA sequencing, and immunohistochemistry data. RESULTS: We developed a 104-gene double-hit signature (DHITsig) that assigned 27% of GCB-DLBCLs to the DHITsig-positive group, with only one half harboring MYC and BCL2 rearrangements (HGBL-DH/TH- BCL2). DHITsig-positive patients had inferior outcomes after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy compared with DHITsig-negative patients (5-year time to progression rate, 57% and 81%, respectively; P < .001), irrespective of HGBL-DH/TH- BCL2 status. The prognostic value of DHITsig was confirmed in an independent validation cohort. DHITsig-positive tumors are biologically characterized by a putative non-light zone germinal center cell of origin and a distinct mutational landscape that comprises genes associated with chromatin modification. A new NanoString assay (DLBCL90) recapitulated the prognostic significance and RNA sequencing assignments. Validating the association with HGBL-DH/TH- BCL2, 11 of 25 DHITsig-positive-transformed follicular lymphomas were classified as HGBL-DH/TH- BCL2 compared with zero of 50 in the DHITsig-negative group. Furthermore, the DHITsig was shared with the majority of B-cell lymphomas with high-grade morphology tested. CONCLUSION: We have defined a clinically and biologically distinct subgroup of tumors within GCB-DLBCL characterized by a gene expression signature of HGBL-DH/TH- BCL2. This knowledge has been translated into an assay applicable to routinely available biopsy samples, which enables exploration of its utility to guide patient management.
PURPOSE: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to understand the biologic underpinnings of HGBL-DH/TH with BCL2 rearrangements (HGBL-DH/TH- BCL2) and diffuse large B-cell lymphoma (DLBCL) morphology through examination of gene expression. PATIENTS AND METHODS: We analyzed RNA sequencing data from 157 de novo germinal center B-cell-like (GCB)-DLBCLs, including 25 with HGBL-DH/TH- BCL2, to define a gene expression signature that distinguishes HGBL-DH/TH- BCL2 from other GCB-DLBCLs. To assess the genetic, molecular, and phenotypic features associated with this signature, we analyzed targeted resequencing, whole-exome sequencing, RNA sequencing, and immunohistochemistry data. RESULTS: We developed a 104-gene double-hit signature (DHITsig) that assigned 27% of GCB-DLBCLs to the DHITsig-positive group, with only one half harboring MYC and BCL2 rearrangements (HGBL-DH/TH- BCL2). DHITsig-positive patients had inferior outcomes after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy compared with DHITsig-negativepatients (5-year time to progression rate, 57% and 81%, respectively; P < .001), irrespective of HGBL-DH/TH- BCL2 status. The prognostic value of DHITsig was confirmed in an independent validation cohort. DHITsig-positive tumors are biologically characterized by a putative non-light zone germinal center cell of origin and a distinct mutational landscape that comprises genes associated with chromatin modification. A new NanoString assay (DLBCL90) recapitulated the prognostic significance and RNA sequencing assignments. Validating the association with HGBL-DH/TH- BCL2, 11 of 25 DHITsig-positive-transformed follicular lymphomas were classified as HGBL-DH/TH- BCL2 compared with zero of 50 in the DHITsig-negative group. Furthermore, the DHITsig was shared with the majority of B-cell lymphomas with high-grade morphology tested. CONCLUSION: We have defined a clinically and biologically distinct subgroup of tumors within GCB-DLBCL characterized by a gene expression signature of HGBL-DH/TH- BCL2. This knowledge has been translated into an assay applicable to routinely available biopsy samples, which enables exploration of its utility to guide patient management.
Authors: Daisuke Ennishi; Anja Mottok; Susana Ben-Neriah; Hennady P Shulha; Pedro Farinha; Fong Chun Chan; Barbara Meissner; Merrill Boyle; Christoffer Hother; Robert Kridel; Daniel Lai; Saeed Saberi; Ali Bashashati; Sohrab P Shah; Ryan D Morin; Marco A Marra; Kerry J Savage; Laurie H Sehn; Christian Steidl; Joseph M Connors; Randy D Gascoyne; David W Scott Journal: Blood Date: 2017-03-28 Impact factor: 22.113
Authors: A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt Journal: Nature Date: 2000-02-03 Impact factor: 49.962
Authors: Gabriel D Victora; David Dominguez-Sola; Antony B Holmes; Stephanie Deroubaix; Riccardo Dalla-Favera; Michel C Nussenzweig Journal: Blood Date: 2012-06-26 Impact factor: 22.113
Authors: Kerry J Savage; Nathalie A Johnson; Susana Ben-Neriah; Joseph M Connors; Laurie H Sehn; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne Journal: Blood Date: 2009-08-24 Impact factor: 22.113
Authors: Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp Journal: Nat Med Date: 2018-04-30 Impact factor: 53.440
Authors: Roland Schmitz; George W Wright; Da Wei Huang; Calvin A Johnson; James D Phelan; James Q Wang; Sandrine Roulland; Monica Kasbekar; Ryan M Young; Arthur L Shaffer; Daniel J Hodson; Wenming Xiao; Xin Yu; Yandan Yang; Hong Zhao; Weihong Xu; Xuelu Liu; Bin Zhou; Wei Du; Wing C Chan; Elaine S Jaffe; Randy D Gascoyne; Joseph M Connors; Elias Campo; Armando Lopez-Guillermo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Kevin Tay Kuang Wei; Andrew D Zelenetz; John P Leonard; Nancy L Bartlett; Bao Tran; Jyoti Shetty; Yongmei Zhao; Dan R Soppet; Stefania Pittaluga; Wyndham H Wilson; Louis M Staudt Journal: N Engl J Med Date: 2018-04-12 Impact factor: 91.245
Authors: Ryan D Morin; Maria Mendez-Lago; Andrew J Mungall; Rodrigo Goya; Karen L Mungall; Richard D Corbett; Nathalie A Johnson; Tesa M Severson; Readman Chiu; Matthew Field; Shaun Jackman; Martin Krzywinski; David W Scott; Diane L Trinh; Jessica Tamura-Wells; Sa Li; Marlo R Firme; Sanja Rogic; Malachi Griffith; Susanna Chan; Oleksandr Yakovenko; Irmtraud M Meyer; Eric Y Zhao; Duane Smailus; Michelle Moksa; Suganthi Chittaranjan; Lisa Rimsza; Angela Brooks-Wilson; John J Spinelli; Susana Ben-Neriah; Barbara Meissner; Bruce Woolcock; Merrill Boyle; Helen McDonald; Angela Tam; Yongjun Zhao; Allen Delaney; Thomas Zeng; Kane Tse; Yaron Butterfield; Inanç Birol; Rob Holt; Jacqueline Schein; Douglas E Horsman; Richard Moore; Steven J M Jones; Joseph M Connors; Martin Hirst; Randy D Gascoyne; Marco A Marra Journal: Nature Date: 2011-07-27 Impact factor: 49.962
Authors: Anja Mottok; George Wright; Andreas Rosenwald; German Ott; Colleen Ramsower; Elias Campo; Rita M Braziel; Jan Delabie; Dennis D Weisenburger; Joo Y Song; Wing C Chan; James R Cook; Kai Fu; Tim Greiner; Erlend Smeland; Harald Holte; Kerry J Savage; Betty J Glinsmann-Gibson; Randy D Gascoyne; Louis M Staudt; Elaine S Jaffe; Joseph M Connors; David W Scott; Christian Steidl; Lisa M Rimsza Journal: Blood Date: 2018-09-26 Impact factor: 25.476
Authors: Grzegorz S Nowakowski; Annalisa Chiappella; Thomas E Witzig; Michele Spina; Randy D Gascoyne; Lei Zhang; Jocelyne Flament; Jacqueline Repici; Umberto Vitolo Journal: Future Oncol Date: 2016-04-18 Impact factor: 3.404
Authors: Zijun Y Xu-Monette; Hongwei Zhang; Feng Zhu; Alexandar Tzankov; Govind Bhagat; Carlo Visco; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Eric D Hsi; Hua You; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Benjamin M Parsons; J Han van Krieken; Miguel A Piris; Jane N Winter; Fredrick B Hagemeister; Babak Shahbaba; Ivan De Dios; Hong Zhang; Yong Li; Bing Xu; Maher Albitar; Ken H Young Journal: Blood Adv Date: 2020-07-28
Authors: Fabienne Lucas; Kerry A Rogers; Bonnie K Harrington; Rosa Lapalombella; Alexander Pan; Lianbo Yu; Justin Breitbach; Ralf Bundschuh; Virginia M Goettl; Zachary A Hing; Parviz Kanga; Rose Mantel; Deepa Sampath; Lisa L Smith; Ronni Wasmuth; Danielle K White; Pearlly Yan; John C Byrd; Jennifer A Woyach Journal: Clin Cancer Res Date: 2019-07-11 Impact factor: 12.531
Authors: Laura K Hilton; Jeffrey Tang; Susana Ben-Neriah; Miguel Alcaide; Aixiang Jiang; Bruno M Grande; Christopher K Rushton; Merrill Boyle; Barbara Meissner; David W Scott; Ryan D Morin Journal: Blood Date: 2019-10-31 Impact factor: 22.113
Authors: R Andrew Harkins; Andres Chang; Sharvil P Patel; Michelle J Lee; Jordan S Goldstein; Selin Merdan; Christopher R Flowers; Jean L Koff Journal: Expert Rev Hematol Date: 2019-09-12 Impact factor: 2.929
Authors: Christopher K Rushton; Sarah E Arthur; Miguel Alcaide; Matthew Cheung; Aixiang Jiang; Krysta M Coyle; Kirstie L S Cleary; Nicole Thomas; Laura K Hilton; Neil Michaud; Scott Daigle; Jordan Davidson; Kevin Bushell; Stephen Yu; Ryan N Rys; Michael Jain; Lois Shepherd; Marco A Marra; John Kuruvilla; Michael Crump; Koren Mann; Sarit Assouline; Joseph M Connors; Christian Steidl; Mark S Cragg; David W Scott; Nathalie A Johnson; Ryan D Morin Journal: Blood Adv Date: 2020-07-14